Real estate investment company Icade reached an absolute floor today, with its share price at its lowest level ever. Morgan Stanley revised its price target downward on Tuesday, amid a market oriented toward decline.
Historic Low of €17.78 Broken Following Morgan Stanley's Revision
Icade recorded a historic record low on Tuesday at €17.78, erasing the previous floor of €17.79. The stock declined 2.25% during the session, after breaking its support at €18.19 without returning to it. This technical breakdown occurred on the same day Morgan Stanley lowered its price target from €23.00 to €21.00, while maintaining its rating at "market weight".
Even revised, this target of €21.00 implies a rebound potential of nearly 18% compared to the current price — reflecting the significant gap between the current valuation and that retained by the analyst. According to the consensus of surveyed analysts, the stock is trading at approximately 5.9 times the expected earnings of the current fiscal year, a modest multiple for a listed real estate investment company.
Three Moving Averages Breached Downward, Decline Intensifies Over One Month
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The decline extends beyond today's event alone: over one month, Icade stock has fallen 8.11%, and 15.57% over three months. The price at €17.78 is trading significantly below the 20-day MA (€18.93, a 6.08% gap), the 50-day MA (€19.01, a 6.47% gap) and the 200-day MA (€20.27, a 12.28% gap). These three moving averages, all above the price, paint a coherent bearish configuration.
The RSI at 36 is approaching the oversold zone without having crossed it yet, reflecting persistent selling pressure over recent weeks. The SBF 120 is declining 0.49% during the session, in a broadly weaker market, while the VIX surges more than 10% intraday, a sign of increased volatility tension. The underlying momentum remains negative: the stock has never closed lower, and the next identified technical level now stands at the resistance of €19.74, representing a gap of nearly 11% above the current price.
Confirmation de la guidance annuelle 2026 avec un CFNC Groupe attendu entre 2,90 € et 3,10 € par action
Risks mentioned
Baisse de valeur du patrimoine de -3,1 % à périmètre constant, dont -2,8 % sur les bureaux
Réversion négative attendue sur les renouvellements de baux, potentiel de -7,1 % sur les loyers faciaux
Coût moyen de la dette en hausse à 1,85 %, attendu à environ 2 % fin 2026 ; ICR dégradé à 3,8x
Opportunities identified
Promesse de vente des actifs de santé au Portugal, environ 75 M€ en quote-part Icade
Acquisition des 49 % de la Tour Eqho avec un rendement supérieur à 8 %, relutive sur le CFNC
Réservations résidentielles en hausse de 11,9 % en volume et 6,4 % en valeur
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.